Please assess the completion status of the following clinical trial:

Trial Title: Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* postmenopausal women, defined as:~* 12 months of spontaneous amenorrhea;~* OR 6 months of spontaneous amenorrhea with serum Follicle Stimulating Hormone~(FSH) levels \>40 mIU/mL;~* OR 6 weeks post surgical bilateral oophorectomy with or without hysterectomy.~* In case the menopausal status of a subject was unclear because of a hysterectomy, the serum FSH level had to be \>40 mIU/mL. If the date of the last menstruation was not clear because of perimenopausal hormone use, then the subject had to have a serum FSH level \>40 mIU/mL after completion of a washout period (see exclusion criteria below); be \>= 40 and \<= 65 years of age;~* have a body mass index (BMI) \>= 18 and \<= 32 kg/m\^2;~* minimum of 7 moderate to severe hot flushes per day or 50 per week, as quantified from daily diary recordings during at least 7 days preceding randomization to trial medication;~* able to handle the electronic diary device after training and having at least 80% compliance on complete daily diary entries during the period prior to randomization;~* give voluntary written Informed Consent (IC) after the scope and nature of the investigation had been explained, before screening evaluations.~Exclusion Criteria:~* history or presence of any malignancy, except non-melanoma skin cancers~* any clinically unstable or uncontrolled renal, hepatic, endocrine,~respiratory, hematological, neurological, cardiovascular, or cerebrovascular disease that would put the subject at safety risk or mask measure of efficacy~* history of seizures or epilepsy; history or presence of clinically significant depression or other psychiatric disorder which, in the opinion of the investigator, might compromise or confound the participant's participation in the trial; abnormal clinically relevant vaginal bleeding~* any clinically relevant (opinion of investigator) abnormal finding during physical, gynecological and breast examination at screening; abnormal, clinically significant results of mammography. Mammography had to have been performed within the last 9 months prior to screening, otherwise it had to be done before inclusion into the trial. For non-US sites, if local laws or guidelines did not allow or advise such frequent mammograms, the documented local laws or guidelines were to be followed; abnormal cervical smear test results (corresponding to Pap III and higher, including Low-Grade Squamous Intraepithelial Lesion (LSIL), High-Grade Squamous Intraepithelial Lesion (HSIL), Cervical Intraepithelial Neoplasia (CIN) 1 and higher). A cervical smear had to have been performed within the last 9 months prior to screening, otherwise it had to be done before inclusion into the trial; hematological or biochemical values at screening outside the reference ranges considered clinically relevant in the opinion of the investigator~* high blood pressure (BP) (sitting systolic BP \>170 mmHg and/or diastolic BP \>100 mmHg)~* use of any drug product containing estrogens, progestins, androgens, or tibolone prior to screening (and up to and including randomization) within specified time frames

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive placebo, encapsulated tablets, orally (PO), once daily (QD) for up to 12 weeks
- Esmirtazapine 2.25 mg (Type: EXPERIMENTAL): Participants receive esmirtazapine 2.25 mg, encapsulated tablets, PO, QD for up to 12 weeks
- Esmirtazapine 4.5 mg (Type: EXPERIMENTAL): Participants receive esmirtazapine 4.5 mg, encapsulated tablets, PO, QD for up to 12 weeks
- Esmirtazapine 9 mg (Type: EXPERIMENTAL): Participants receive esmirtazapine 9 mg, encapsulated tablets, PO, QD for up to 12 weeks
- Esmirtazapine 18 mg (Type: EXPERIMENTAL): Participants receive esmirtazapine 18 mg, encapsulated tablets, PO, QD for up to 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).